SCHEMBL4199836

SCHEMBL4199836

CS(=O)(=O)Nc1ccccc1OC[C@H]1CO1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
GLA P06280 1/20 0.56
HSD17B10 Q99714 2/20 0.49
TDP1 Q9NUW8 1/20 0.45
MRGPRX1 Q96LB2 3/20 0.44
PKM P14618 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
CYP19A1 P11511 1/20 0.41
KEAP1 Q14145 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
HIF1A Q16665 1/20 0.41
NFE2L2 Q16236 1/20 0.41
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199842 1.00 ALDH1A1 (0.56) ALDH1A1GLAHSD17B10TDP1MRGPRX1
SCHEMBL14798300 0.82 MRGPRX1 (0.57) ALDH1A1HSD17B10MRGPRX1KDM4EHPGD
SCHEMBL6245211 0.78 ALDH1A1 (0.61) ALDH1A1GLATDP1PKMLMNA
SCHEMBL6245216 0.78 ALDH1A1 (0.61) ALDH1A1GLATDP1PKMLMNA
SCHEMBL1936782 0.77 SMN1; SMN2 (0.48) ALDH1A1TDP1PKMLMNAGAA
SCHEMBL6480570 0.77 SMN1; SMN2 (0.48) ALDH1A1TDP1PKMLMNAGAA
SCHEMBL3814852 0.77 BRD4 (0.57) ALDH1A1GLAHSD17B10LMNAGAA
SCHEMBL3809740 0.77 BRD4 (0.57) ALDH1A1GLAHSD17B10LMNAGAA
SCHEMBL1474972 0.77 MRGPRX1 (0.52) HSD17B10TDP1MRGPRX1CYP19A1
SCHEMBL4789716 0.77 ALDH1A1 (0.55) ALDH1A1GLATDP1MRGPRX1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138502-A1 Ph-dependent nmda receptor antagonists EMORY UNIVERSITY 2004-07-15 US claimed
US-20090023791-A1 PH-dependent NMDA receptor antagonists EMORY UNIVERSITY (US) 2009-01-22 US disclosed
US-7375136-B2 pH-dependent NMDA receptor antagonists EMORY UNIVERSITY (US) 2008-05-20 US disclosed
EP-1436258-A4 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS UNIV EMORY (US) 2005-03-23 EP disclosed
US-20040138502-A1 Ph-dependent nmda receptor antagonists EMORY UNIVERSITY 2004-07-15 US disclosed
EP-1436258-A2 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS Emory University (US) 2004-07-14 EP disclosed
WO-2002072542-A2 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS EMORY UNIVERSITY (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023791-A1 PH-dependent NMDA receptor antagonists GRIN1, GRIA4, GRIA1 ALDH1A1 2194/4885GLA 1133/4885HSD17B10 4326/4885
US-20040138502-A1 Ph-dependent nmda receptor antagonists GRIN1, GRIN2B, GRIN3A ALDH1A1 2602/4885GLA 1073/4885HSD17B10 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.